{
    "id": "3620b4be-63bc-dd15-e063-6394a90ac3b4",
    "indications": "Valproic Acid Capsules are indicated for: Monotherapy and adjunctive therapy of complex partial seizures; sole and adjunctive therapy of simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 )",
    "contraindications": "Valproic Acid Capsules are intended for oral administration. ( 2.1 ) Simple and Complex Absence Seizures: Start at 10 to 15 mg/kg/day, increasing at 1-week intervals by 5 to 10 mg/kg/week until seizure control or limiting side effects ( 2.1 ) Safety of doses above 60 mg/kg/day is not established ( 2.1 , 2.2 )",
    "warningsAndPrecautions": "Each white, oblong soft-gelatin capsule is imprinted PA2120, contains 250 mg valproic acid\n                  \n                  NDC: 70518-0079-00\n                  NDC: 70518-0079-01\n                  NDC: 70518-0079-02\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 100 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  \n                  The softgels should be protected from moisture and humidity and stored between 59 to 77°F (15 to 25°C) as per the container label. Dispense in a tight, light-resistant container as defined in the USP/NF.\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "Valproic Acid Capsules should not be administered to patients with hepatic disease or significant hepatic dysfunction\n  \n   [see Warnings and Precautions (\n   \n    5.1)]\n  \n   .\n \n  \n                     Valproic Acid is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder\n  \n   [see Warnings and Precautions (\n   \n    5.1)]\n  \n   .\n \n  \n                     Valproic Acid is contraindicated in patients with known hypersensitivity to the drug\n  \n   [see Warnings and Precautions (\n   \n    5.12)]\n  \n   .\n \n  \n                     Valproic Acid is contraindicated in patients with known urea cycle disorders\n  \n   [see Warnings and Precautions (\n   \n    5.6)]\n  \n   .\n \n  \n                     For use in prophylaxis of migraine headaches: Valproic Acid is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception \n  \n   [see Warnings and Precautions (\n   \n    5.2,\n                           5.3,\n   \n    5.4\n                        \n                        ) and Use in Specific Populations (\n                        \n                           8.1\n                        \n                        )].",
    "ingredients": [
        {
            "name": "CORN OIL",
            "code": "8470G57WFM"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "VALPROIC ACID",
            "code": "614OI1Z5WI"
        }
    ],
    "organization": "REMEDYREPACK INC.",
    "name": "Valproic Acid",
    "effectiveTime": "20250527"
}